Price
CHART BY
Frequently asked questions
What is Grail's market capitalization?
The market capitalization of Grail is $3.40B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Grail?
Grail's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$9.748. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Grail's stock?
Currently, 10 analysts cover Grail's stock, with a consensus target price of $77.00. Analyst ratings provide insights into the stock's expected performance.
What is Grail's revenue over the trailing twelve months?
Over the trailing twelve months, Grail reported a revenue of $165.26M.
What is the EBITDA for Grail?
Grail's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$378.46M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Grail?
Grail has a free cash flow of -$296.16M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Grail have, and what sector and industry does it belong to?
Grail employs approximately 910 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Grail's shares?
The free float of Grail is 41.96M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.40B
- EPS (TTM)
- -$9.748
- Free Float
- 41.96M
- Revenue (TTM)
- $165.26M
- EBITDA (TTM)
- -$378.46M
- Free Cashflow (TTM)
- -$296.16M
Pricing
- 1D span
- $76.02$76.63
- 52W span
- $37.00$118.53
Analyst Ratings
The price target is $77.00 and the stock is covered by 10 analysts.
Buy
5
Hold
5
Sell
0
Information
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
- Employees
- 910
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- Primary Ticker
- GRAL
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet